共 50 条
- [21] Discovery of a Potent and Selective ROMK Inhibitor with Pharmacokinetic Properties Suitable for Preclinical EvaluationACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (07): : 747 - 752Walsh, Shawn P.Shahripour, AurashTang, HaifengTeumelsan, NardosFrie, JessicaZhu, YupingPriest, Birgit T.Swensen, Andrew M.Liu, JessicaMargulis, MichaelVisconti, RichardWeinglass, AdamFelix, John P.Brochu, Richard M.Bailey, TimothyThomas-Fowlkes, BrandeAlonso-Galicia, MagdalenaZhou, XiaoyanPai, Lee-YuhCorona, AaronHampton, CarynHernandez, MelbaBentley, RossChen, JingShah, KashmiraMetzger, JosephForrest, MichaelOwens, KarenTong, VincentHa, SookheeRoy, SophieKaczorowski, Gregory J.Yang, LihuParmee, EmmaGarcia, Maria L.Sullivan, KathleenPasternak, Alexander
- [22] Discovery of a potent and selective Axl inhibitor in preclinical modelBIOORGANIC & MEDICINAL CHEMISTRY, 2021, 39Inoue, SatoshiYamane, YoshinobuTsukamoto, ShuntaroAzuma, HiroshiNagao, SatoshiMurai, NorioNishibata, KyokoFukushima, SayoIchikawa, KenjiNakagawa, TakayukiSugi, Naoko HataIto, DaisukeKato, YuGoto, AyaKakiuchi, DaiUeno, TakashiMatsui, JunjiMatsushima, Tomohiro
- [23] Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia modelsInvestigational New Drugs, 2020, 38 : 1272 - 1281Li WangChen HuAoli WangCheng ChenJiaxin WuZongru JiangFengming ZouKailin YuHong WuJuan LiuWenliang WangZuowei WangBeilei WangZiping QiQingwang LiuWenchao WangLili LiJian GeJing LiuQingsong Liu
- [24] Structure-based design of potent CDK4 selective inhibitor.ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U24 - U24Honma, THayashi, KKawanishi, NYoshizumi, THashimoto, NSugimoto, TNakamura, KTakaki, TMachida, TFukasawa, KHirai, HIwama, TIkeura, CIkuta, MKamata, KSuzuki-Takahashi, IHayama, T
- [25] Current progress and novel strategies that target CDK12 for drug discoveryEUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 240Lei, PengZhang, JifaLiao, PeiyuRen, ChangyuWang, JiaxingWang, Yuxi
- [26] Preclinical disposition and pharmacokinetics of volitinib, a novel selective cMet inhibitor.CANCER RESEARCH, 2013, 73 (08)Gu, YiSai, YangWang, JianXia, SumeiWang, GuanglinZhao, YuanshengZhang, LiYang, WenqingDai, GuangxiuZhang, WeihanGong, QisunTian, ZhenpingSu, Weiguo
- [27] Preclinical evaluation of TQB3616, a highly potent and selective small-molecule CDK4/6 inhibitorCANCER RESEARCH, 2018, 78 (13)Xu ZhaobingHu LihongLiu YingchunDing, Charles Z.Zhu, XiaoyuChen, ChenZhu, YusongWu, JiahuWu, DongdongChen, ShuhuiZhang, XiquanYang, LingTian, Xin
- [28] Preclinical development of a highly potent and selective dual inhibitor of CDK4/6 for the treatment of cancerCANCER RESEARCH, 2018, 78 (13)Bantie, LaychiluhTadesse, SolomonLikisa, JimmaYu, MingfengNoll, BenjaminAlbrecht, HugoMilne, RobertWang, Shudong
- [29] Discovery of a novel and highly selective CDK9 kinase inhibitor (JS']JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia modelsINVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1272 - 1281Wang, LiHu, ChenWang, AoliChen, ChengWu, JiaxinJiang, ZongruZou, FengmingYu, KailinWu, HongLiu, JuanWang, WenliangWang, ZuoweiWang, BeileiQi, ZipingLiu, QingwangWang, WenchaoLi, LiliGe, JianLiu, JingLiu, Qingsong
- [30] In vitro evaluation of apixaban, a novel, potent, selective and orally bioavailable factor Xa inhibitor.BLOOD, 2006, 108 (11) : 112B - 112BLuettgen, Joseph M.Bozarth, Tracy A.Bozarth, Jeffrey M.Barbera, Frank A.Lam, Patrick Y.Quan, Mimi L.Pinto, Donald J.Wexler, Ruth R.Rendina, Alan R.Knabb, Robert M.